Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02115


Purpose:

The purpose of this study is to find out what effects the preoperative therapy cisplatin will have on patients with early stage estrogen receptor-negative (ER-), progesterone receptor-negative (PR-), or HER-2 negative breast cancer.


Study summary:

Before starting treatment patients will undergo placement of a clip into the tumor bed so the surgeon can locate the site of the tumor at the time of surgery. Patients will receive cisplatin intravenously once every three weeks for a total of 4 cycles or 12 weeks of treatment. After completion of cisplatin, patients will undergo surgery to remove any tumor that remains and to assess the tissue to see if tumor cells remain in the breast. Patients may receive a second breast MRI and biopsy 7-14 days after treatment begins to see whether we can identify tumors that will ultimately respond to cisplatin with a rapid evaluation. Patients will receive study treatment for approximately 12 weeks unless unacceptable toxicity occurs. After surgery patients will receive standard adjuvant therapy based on discussion with their physician. Follow-up progress will occur for several years.


Criteria:

Inclusion Criteria: - All tumors must be ER-, PR- and HER-2 negative. - Age > 18 years - ECOG performance status of less than or equal to 1 - Absolute neutrophil count (ANC) > 1,500/mm3 - Hemoglobin > 9mm/dl - Platelets > 100,000/mm3 - Creatinine < 1.5mg/dl - Glucose < 200mg/dl - Bilirubin < 1.5 x upper limit of normal (ULN) - SGOT < 3.0 x ULN Exclusion Criteria: - Prior chemotherapy treatment - Pregnant or breast-feeding women - History of serious illness, medical or psychiatric condition requiring medical management - Uncontrolled infection - Renal dysfunction - Active or severe cardiovascular or pulmonary disease - Peripheral neuropathy of any etiology that exceeds grade 1 - Prior history of malignancy - Uncontrolled diabetes


NCT ID:

NCT00148694


Primary Contact:

Principal Investigator
Judy E. Garber, MD
Dana-Farber Cancer Institute


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02115
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.